Viatris Posts $325.3 Million Loss, Raises Midpoints of 2026 Guidance
Key Facts
On November 5, Viatris reported a U.S. GAAP net loss of $325.3 million in the third quarter of 2026, compared with a loss of $128.2 million a year earlier. Diluted loss per share was $0.28, versus $0.11 in the corresponding quarter of 2025. The company said the loss was mainly due to a higher income tax provision, driven by losses in jurisdictions where little tax benefit can be realized. The accounting results came alongside improvement in adjusted earnings metrics, with adjusted EBITDA rising 4% to $1.1957 billion. Adjusted EPS also increased 6% to $0.71, according to the results statement.
Total revenue was $3.7495 billion, compared with $3.7599 billion in the third quarter of 2025, which the company described as largely stable year over year. Viatris said sales of new products, particularly in developed markets, supported revenue. Strength in its North America business and sales in Greater China also helped offset other headwinds. In Greater China, reported sales rose 14% and operational sales rose 10% year over year. By contrast, sales in emerging markets fell 7% on a reported basis and 6% operationally, while supply constraints in Europe and emerging markets, along with additional competition for certain products, weighed on results.
The sales mix showed a divergence between the two drug categories: branded drug sales rose 1% to $2.4614 billion in the quarter. Generic drug sales fell 3% to $1.2733 billion compared with the same period a year earlier. The company estimated that supply constraints reduced revenue by about $100 million in the third quarter. It also expects an impact of about $100 million in the fourth quarter of 2026. It said growth in new products and developed markets, strength in its North America business and sales in Greater China offset some of these constraints, along with additional competition for specific products.
For the first nine months of 2026, revenue was $11.0233 billion, up 4% on a reported basis from $10.5963 billion in the corresponding period of 2025, while operational growth was 2%. Adjusted EBITDA for the period rose 9% to $3.4335 billion, compared with $3.1569 billion. Adjusted EPS climbed 12% to $1.99, versus $1.78 in the first nine months of 2025. U.S. GAAP cash generated from operating activities was $899.4 million in the third quarter. Free cash flow reached $813.7 million, up 24% from the third quarter of the previous year.
Viatris raised the midpoint of its full-year financial guidance ranges, setting the revenue midpoint at $14.8 billion, compared with $14.75 billion in its August guidance. It raised the adjusted EBITDA midpoint to $4.5 billion from $4.4 billion. It also increased the midpoint of its adjusted EPS guidance to $2.60 from $2.52. Chief Executive Scott Smith said the quarter's results “reflect strong execution and reinforce our confidence in the growth trajectory of our business,” linking this to momentum in the core business, pipeline progress and a comprehensive strategic review of the company. The company does not provide guidance for U.S. GAAP net income or loss per share, and its 2026 figures do not include any contribution from the planned acquisition of Pacira BioSciences.
The company said it generated about $115 million in revenue from new products in the third quarter and expects these products to generate about $450 million in revenue in 2026. In August, it had raised its forecast range for this revenue to $450–550 million, after recording about $287 million in the first nine months, then kept its estimate at about $450 million for the year in November. The acquisition of Pacira BioSciences is expected to close by the end of November 2026, while the annual guidance excludes the deal's contribution. At its manufacturing facility in Nashik, India, Viatris expects production to resume in the first quarter of 2027 after voluntarily suspending manufacturing in October to focus on remediation. It said the U.S. Food and Drug Administration classified the outcome of the facility inspection as “Official Action Indicated” following inspection observations issued in May.
In trading, VTRS closed at $19.22 on November 4, according to EL7 data. After the results were announced, the stock rose 0.31% in premarket trading on November 5, according to Reuters coverage published via Investing.com. The coverage said adjusted EPS exceeded analysts' estimate of $0.64. It added that revenue, at $3.75 billion according to the coverage, fell short of the $3.8 billion estimate. The results review webcast was scheduled for November 5 at 8:30 a.m. U.S. Eastern Time.